Library · Immune · Liver protection and immune system regulation
Livagen (Lys-Glu-Asp-Ala)
KEDA peptide, Immunomodulating tetrapeptide, Liver bioregulator peptide
Short synthetic peptide bioregulator (Lys-Glu-Asp-Ala) studied for modulating chromatin structure and gene expression, potentially reversing age-related DNA changes. Acts on immune, liver, and gut tissue, mainly researched in anti-aging and immune-normalization contexts.
Research score 50/100. Reference only, not a dose.
- Liver Protection
- Immune Boosting
- Anti-inflammatory
- Detoxification
- US status
- Research Chemical
- Approval
- Research Chemical Only
- Evidence
- Used in Russia. Limited specific 'Livagen' clinical trials in Western databases (2020-2025).
- Research score
- 50 / 100
- Indication
- Research Only - No Medical Indication
- Origin
- Russia
- Source category
- Immune System
- Status group
- Research chemical
Mechanism
Interacts with nuclear factors in liver cells to shift gene expression toward anti-inflammatory cytokines over pro-inflammatory ones via JAK/STAT signaling, while supporting hepatocyte survival and regeneration through NF-κB-linked protective pathways and boosted detox enzyme expression.
Safety file
Considered safe as a bioregulator, with only theoretical mild side effects.
- Injection site reactions
- Mild fatigue
- Temporary immune system fluctuations